 CRANBURY, N.J., Aug. 13, 2021 GLOBE NEWSWIRE -- PMV Pharmaceuticals, Inc. Nasdaq: PMVP, a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies designed to target p53 mutants, today reported financial results for the second quarter ended June 30, 2021 and provided corporate highlights. 